Osmose Welcomes New CFO Harsha Tank to Executive Leadership Team
Osmose, a global industry-leading asset management solutions company for electric utilities, telecommunications providers, and renewable energy generators, names new CFO.
Harsha brings over 20 years of experience driving strategic, transformative growth, operational excellence, and financial performance across global organizations. She has a diverse portfolio of industry experience, including legal services, food and facilities management, software, semiconductor manufacturing, and oil & gas transportation, bringing a wealth of perspective and leadership to Osmose.
Prior to joining Osmose, Harsha served as CFO at Veritext Legal Solutions, a leader in litigation support services. She also spent over a decade at Sodexo, a global leader in quality-of-life-services, in senior financial roles, including Regional CFO positions supporting healthcare and Fortune 100 clients, and later as CFO of Sodexo's Global Supply Chain function. Earlier in her career, she held key financial leadership roles at Intralinks, Inc. (NYSE: IL), Open Solutions (Fiserv), Jazz Technologies, and Pacific Energy Partners (NYSE; PPX). Harsha is also a Certified Public Accountant (CPA).
'We are thrilled to welcome Harsha to Osmose,' said Osmose CEO, Mike Adams. 'She brings a unique combination of financial discipline and strategic insight, and her strong services background will strengthen Osmose's mission to help utilities extend the life of their structural assets. I'd also like to thank Jeff for his contributions over the past three years and wish him all the best in his retirement. Jeff's legacy will be one of creating a more scalable financial ecosystem that I am sure Harsha will continue to build on.'
About Osmose Utilities Services, Inc.
Osmose Utilities Services, Inc. is a market-leading provider of critical resiliency, assessment, restoration, and contact voltage testing for electric transmission, distribution, renewable generators, and telecommunications companies in North America, Europe, and Australia. Headquartered in Atlanta, Georgia, the company employs more than 4,000 people. Osmose's multidisciplinary team of field technicians, professional engineers, scientists, product developers, and solutions delivery teams utilize their expertise to identify and mitigate risks to make utility infrastructure safer, longer-lasting, and more resilient, while lowering total costs of ownership. Osmose is a portfolio company of EQT Infrastructure. Learn more at https://www.osmose.com/.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Coherent Corp. Unveils New ACE FL Thulium Fiber Laser for Advanced Medical Treatments
Coherent Corp. (NYSE:COHR) is one of the best NYSE stocks to buy for long term investment. On June 24, Coherent announced the introduction of its new ACE FL series. This thulium fiber laser/TFL system is engineered for therapeutic medical applications, with a primary focus on lithotripsy and the treatment of benign prostatic hyperplasia/BPH. The two-micron ACE FL system offers greater procedural efficiency when compared to older laser technologies such as holmium:YAG systems. Thulium fiber lasers include superior cutting precision for BPH enucleation, which is a compact design to facilitate OEM integration, and improved energy efficiency. A row of precision industrial lasers in action, cutting the most intricate of shapes. The ACE FL platform uses proprietary fiber designs and manufacturing capabilities to offer OEM partners a scalable and high-performance solution for developing next-gen surgical tools. Coherent also simplifies integration by combining the power of the ACE FL series with its established disposable fiber assemblies. Coherent plans to showcase the ACE FL at the LASER World of Photonics Munich 2025 event. Coherent Corp. (NYSE:COHR) develops, manufactures, and markets engineered materials, optoelectronic components & devices, and optical & laser systems and subsystems for the industrial, communications, electronics, and instrumentation markets. While we acknowledge the potential of COHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
38 minutes ago
- Yahoo
Cloudflare Launches AI Crawler Blocking and 'Pay Per Crawl' Model
Cloudflare Inc. (NYSE:NET) is one of the best NYSE stocks to buy for long term investment. On July 1, Cloudflare launched a significant AI Crawler Blocking feature, which gives website owners greater control over how AI models access their content. The initiative, together with the introduction of Cloudflare Log Explorer, aims to support content security. Starting from July 1, every new web domain that signs up for Cloudflare will be prompted to choose whether to allow or block AI crawlers by default. This gives website owners the power to prevent AI bots from scraping data from their sites. Cloudflare also introduced a new 'pay per crawl' model, which allows publishers to charge AI crawlers for content access. A close-up of a server array powering a cloud-services system. AI crawlers are automated bots designed to extract vast amounts of data from websites and other sources to train LLMs developed by big tech companies. The new default blocking builds upon a tool Cloudflare introduced in September last year, which allowed publishers to block AI crawlers with a single click. Additionally, Cloudflare has made its Log Explorer tool generally available as of June 18. The tool provides businesses with access to security and performance insights by allowing them to analyze, investigate, and monitor logs directly within the Cloudflare Dashboard. Cloudflare Inc. (NYSE:NET) is a cloud services provider that delivers a range of services to businesses. While we acknowledge the potential of NET as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceuticals
NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against West Pharmaceutical Services, Inc. ('West' or the 'Company') (NYSE: WST) and reminds investors of the July 7, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements Share Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (a) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products portfolio; (b) West's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to the Company's profit margins due to operational inefficiencies; (c) these margin pressures created the risk of costly restructuring activities, including the Company's exit from continuous glucose monitoring contracts with long-standing customers; and (d) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis. The truth about this fraud was revealed over a series of disclosures culminating on February 13, 2025, when West issued extremely weak 2025 revenue and earnings forecasts. West attributed the disappointing guidance in part to contract manufacturing headwinds, including the loss of two major continuing glucose monitoring customers that had begun transitioning to in-house manufacturing of next-generation devices after West 'made the decision to not participate going forward as our financial thresholds cannot be achieved.' West also revealed that its SmartDose wearable injector devices would be 'margin-dilutive' in 2025 and that it would be 'taking steps to improve [its SmartDose] economics, and all options are on the table.' On this news, West's stock dropped $123.17 per share, a decline of 38 percent, to close at $199.11 on February 13, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding West's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the West Pharmaceutical Services class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
